Navigation Links
Stem Cell Industry Insider Mercedes Walton Discusses President Obama's Stem Cell Executive Order
Date:3/17/2009

- Mercedes Walton, Chairman and CEO of Cryo-Cell International and C'elle(SM), Welcomes President Obama's Stem Cell Decision -

OLDSMAR, Fla., March 17 /PRNewswire-FirstCall/ -- As the CEO of Cryo-Cell International, the nation's most established private family cord blood bank, Mercedes Walton has been an active participant in the stem cell and cord blood industry since 2000. She has seen first-hand the changes that have taken place over the past decade and is pleased by President Obama's Executive Order, signed March 9, 2009, which reverses a 2001 Executive Order banning federal funds for embryonic stem cell research.

"We are excited to hear the news that President Obama reversed existing legislation regarding the use of federal funds for stem cell research. Although there is much work to be done to formulate ethical practices and policies on how best to proceed with certain forms of stem cell research, the American public can certainly find common ground in our collective interest to develop advanced stem cell therapies that may provide new breakthrough cures and treatments for a multitude of life-threatening and devastating diseases in the future," said Walton.

The Executive Order is lauded as affirming the American government's belief in scientific progress and offers hope of better treatments and cures to millions of Americans suffering from debilitating diseases such as stroke, heart disease, diabetes, Alzheimer's and Parkinson's. The Executive Order reflects the opinions of a majority of Americans who support increased federal funding for stem cell research due to the expansive lifesaving potential it holds.

Walton went on to say, "As a global industry leader in stem cell innovation, the responsible and productive use of stem cell research is of the utmost importance to all of us at Cryo-Cell and C'elle."

A pioneer in the non-controversial stem cell arena, Walton co-invented Cryo-Cell's novel menstrual stem cell technology portfolio along with Dr. Julie Allickson, Cryo-Cell's V.P. of Research & Development and Laboratory Operations. C'elle(SM) was commercialized in 2007 and is the first and only service available that empowers women to collect and cryopreserve highly prolific stem cells harvested from their own menstrual fluid for potential stem cell therapies in the future. Cryo-Cell has served over 175,000 clients worldwide and led the cord blood banking industry with the successfully establishment of a state-of-the-art Good Manufacturing Practice/Good Tissue Practice (cGMP/cGTP) laboratory processing facility well ahead of emerging regulation and competition.

For more information, or to schedule an interview with Cryo-Cell International executives, please contact Monica Kozak at (203) 545-1055; monica@horizonmarketing.com.

About Cryo-Cell International, Inc. (OTC Bulletin Board: CCEL)

Based in Oldsmar, Florida, with over 175,000 clients worldwide, Cryo-Cell is one of the largest and most established family cord blood banks. ISO 9001:2000 certified and accredited by the AABB, Cryo-Cell operates in a state-of-the-art Good Manufacturing Practice and Good Tissue Practice (cGMP/cGTP)-compliant facility. Cryo-Cell is a publicly traded company. OTC Bulletin Board Symbol: CCEL. For more information, please call 1-800-STOR-CELL (1-800-786-7235) or visit www.cryo-cell.com.

About C'elle

Based in Oldsmar, Florida, C'elle is the first available service that enables women to collect and cryopreserve stem cells collected from their menstrual flow. C'elle is a proprietary service of Cryo-Cell International, Inc., one of the largest and most established family cord blood banks in the nation. C'elle was developed by researchers at Cryo-Cell following the company's discovery of unique and highly prolific stem cells in menstrual fluid. C'elle has the potential to benefit millions of women worldwide, since stem cells found in menstrual blood may potentially be utilized in a broad range of future regenerative therapies to possibly treat a number of debilitating conditions such as heart disease, stroke and diabetes. C'elle stem cells may also have potential to be used in cosmeceutical applications such as anti-aging and sports medicine. For more information on C'elle, please call 1-877-892-3553 or visit www.celle.com.


'/>"/>
SOURCE Cryo-Cell International, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Ohio Ranks Best in the Midwest for Venture Capital Investment in Health Care Bioscience Industry
2. Advanced Cell Technologys Dr. Robert Lanza Makes List of 100 Most Inspiring People in the Life-Sciences Industry
3. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
4. Favrille CEO to Present at NewsMakers in the Biotech Industry Investment Conference
5. NeurogesX to Present at BioCenturys NewsMakers in the Biotech Industry Conference
6. DURECT Corporation to Present at the NewsMakers in the Biotech Industry Investment Conference
7. TorreyPines Therapeutics to Present at the NewsMakers in the Biotech Industry Conference
8. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
9. Anesiva to Present at BioCenturys NewsMakers in the Biotech Industry Conference on September 6, 2007
10. BioCryst to Present at the BioCentury NewsMakers in the Biotech Industry Conference
11. Suntech to Attend Upcoming Investor Conferences and Industry Events
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded coverage of ... newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for Hemostats and ... synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates the market ...
(Date:10/11/2017)... ... October 11, 2017 , ... ... in its endogenous context, enabling overexpression experiments and avoiding the use of exogenous ... RNA guides is transformative for performing systematic gain-of-function studies. , This complement ...
(Date:10/11/2017)... 11, 2017  VMS BioMarketing, a leading provider of patient ... Clinical Nurse Educator (CNE) network, which will launch this week. ... among health care professionals to enhance the patient care experience ... and other health care professionals to help women who have ... ...
(Date:10/11/2017)... , ... October 11, 2017 , ... ... (FDA) has granted orphan drug designation to SBT-100, its novel anti-STAT3 (Signal Transducer ... treatment of osteosarcoma. SBT-100 is able to cross the cell membrane and bind ...
Breaking Biology Technology:
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
(Date:4/5/2017)... , April 5, 2017 Today HYPR ... that the server component of the HYPR platform is ... providing the end-to-end security architecture that empowers biometric authentication ... HYPR has already secured over 15 million users across ... manufacturers of connected home product suites and physical access ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):